Friday, August 06, 2021 1:13:55 PM
Cash and cash equivalents as of June 30 were $87.2M, which does not include the approximately $42.2M raised in the equity offering on July 19. Management expects its current cash and cash equivalents to be sufficient to fund operations into 2023. "So far this year, we have made outstanding progress with both our selective oral DHODH inhibitor, IMU-838, as well as IMU-935, a highly potent and selective inverse agonist of the transcription factor ROR?t, enabling what we believe will be an eventful and potentially transformative first half of 2022. In particular, we anticipate five data read-outs from clinical trials within the next twelve months, and expect to begin our first phase 3 pro gram very soon. I want to congratulate our entire team for this remarkable momentum," stated Daniel Vitt, CEO and president of Immunic. "In June, we received U.S. Food and Drug Administration (FDA) clearance for our Investigational New Drug (IND) application for the phase 3 ENSURE program of IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS), and the supportive phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS). Initiation of these trials in the second half of this year will mark a major milestone for our lead program. Additionally, we look forward to completing recruitment of our ongoing phase 2 CALDOSE-1 trial of IMU-838 in patients with ulcerative colitis (UC) during the second half of 2021, and reporting top-line data for this potential second key indication for IMU-838 in the first half of 2022."
Recent IMUX News
- Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis • PR Newswire (US) • 09/18/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:05:53 PM
- Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome • PR Newswire (US) • 09/04/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 12:30:38 PM
- Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September • PR Newswire (US) • 08/28/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:17:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 10:45:40 AM
- Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/08/2024 10:30:00 AM
- Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update • PR Newswire (US) • 08/01/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:11:28 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:10:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 10:40:20 AM
- Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec • PR Newswire (US) • 07/24/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 12:31:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 10:40:33 AM
- Immunic Appoints Jason Tardio as Chief Operating Officer and President • PR Newswire (US) • 07/09/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:08:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:07:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:05:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/10/2024 08:05:34 PM
- Immunic to Participate in Industry and Scientific Conferences in June • PR Newswire (US) • 05/28/2024 10:30:00 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/24/2024 08:06:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:20:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM